LRMR Larimar Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1374690 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-18.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-129.8%
ROA-95.2%
ROIC (approx.)-348.7%
Asset turnover—
Leverage & solvency
Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $25.93M | $28.00M | $25.03M | $59.37M | $44.93M | $23.37M | $26.55M | $26.74M |
| SG&A expense | $6.54M | $6.35M | $6.09M | $4.64M | $4.57M | $4.42M | $4.64M | $4.55M |
| Operating income | -$32.46M | -$34.35M | -$31.12M | -$64.02M | -$49.50M | -$27.79M | -$31.19M | -$31.29M |
| Income tax | — | — | — | $0 | $0 | $0 | — | $0 |
| Net income | -$31.14M | -$32.78M | -$29.61M | -$62.50M | -$47.71M | -$26.18M | -$29.28M | -$28.82M |
| EBITDA | -$32.41M | -$34.29M | -$31.05M | -$63.93M | -$49.41M | -$27.70M | -$31.10M | -$31.22M |
| EPS (basic) | — | — | — | — | -0.61 | -0.41 | -0.46 | — |
| EPS (diluted) | — | — | — | — | -0.61 | -0.41 | -0.46 | — |
| Weighted avg. shares (diluted) | — | — | — | — | 78.32M | 64.03M | 63.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $76.99M | $92.69M | $177.91M | $85.41M | $90.14M | $20.59M | $21.13M | $33.22M |
| Short-term investments | $51.67M | $63.58M | $22.47M | $51.44M | $85.30M | $117.94M | $136.40M | $150.24M |
| Current assets | $136.15M | $160.67M | $204.98M | $142.02M | $183.22M | $145.56M | $165.49M | $195.30M |
| PP&E, net | $597,000 | $639,000 | $558,000 | $622,000 | $709,000 | $797,000 | $855,000 | $881,000 |
| Total assets | $140.50M | $165.30M | $208.51M | $145.84M | $187.35M | $149.99M | $170.18M | $200.22M |
| Current liabilities | $35.65M | $34.17M | $47.76M | $64.80M | $45.12M | $26.65M | $22.13M | $24.36M |
| Total liabilities | $39.04M | $37.92M | $50.48M | $67.76M | $48.31M | $30.13M | $25.90M | $28.41M |
| Shareholders' equity | $101.47M | $127.38M | $158.03M | $78.08M | $139.04M | $119.85M | $144.27M | $171.81M |
| Shares outstanding | 104.63M | 103.88M | 103.88M | 83.09M | 85.59M | 64.03M | 64.03M | 63.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$31.19M | -$44.03M | -$44.61M | -$38.53M | -$28.75M | -$19.38M | -$26.54M | -$21.82M |
| Capital expenditure | $28,000 | — | — | $0 | $23,000 | $19,000 | $49,000 | $179,000 |
| Free cash flow | -$31.21M | — | — | -$38.53M | -$28.78M | -$19.40M | -$26.59M | -$21.99M |
| Investing cash flow | $12.43M | -$40.91M | $29.00M | $34.00M | $33.02M | $18.84M | $14.45M | $19.20M |
| Financing cash flow | $3.05M | -$435,000 | $108.11M | -$201,000 | $65.29M | — | — | $36,000 |
| Depreciation & amortization | $57,000 | $62,000 | $64,000 | $87,000 | $88,000 | $87,000 | $88,000 | $77,000 |
| Stock-based compensation | $2.17M | $2.15M | $1.98M | $1.56M | $1.78M | $1.83M | $1.83M | $2.41M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.